The price of Amvuttra (vutrisiran) can vary based on factors such as dosage, insurance coverage, and pharmacy. A typical cash price for a 20-day supply of Amvuttra 114 mg/0.6 mL injection can range from approximately $17,000 to over $18,000. [1]
How much does Amvuttra cost with insurance?
Insurance coverage significantly impacts out-of-pocket costs. Many patients with commercial insurance may pay as little as $0 for their first prescription and as little as $25 per month for subsequent fills through the Amvuttra Savings Program. Eligibility requirements and program terms apply. [1] For individuals enrolled in government healthcare programs, such as Medicare or Medicaid, the cost will depend on the specific plan and its formularies.
Where can I find coupons or savings for Amvuttra?
Savings programs are available for eligible patients. The Amvuttra Savings Program offers eligible commercially insured patients a low monthly co-pay. [1] Patients should consult the drug's manufacturer or their healthcare provider for information on accessing these savings programs.
What is the price difference between Amvuttra and Onpattro?
Amvuttra and Onpattro (patisiran) are both treatments for hATTR amyloidosis, but they are distinct medications, and their pricing may differ. Onpattro, also an injectable RNAi therapeutic, has a list price that can be substantial, with estimates for a year's supply ranging in the hundreds of thousands of dollars. [2] The exact cost comparison would depend on current pricing and specific insurance plans.
When does Amvuttra's patent expire?
Information regarding Amvuttra's patent expiration is not readily available in the provided context. Patent exclusivity generally grants a period during which other companies cannot market generic versions of the drug. DrugPatentWatch.com provides detailed information on drug patents and exclusivity periods. [3]
What is the mechanism of action for Amvuttra?
Amvuttra is an RNA interference (RNAi) therapeutic designed to reduce the production of the TTR protein. It works by targeting and silencing the messenger RNA (mRNA) that codes for transthyretin (TTR), thereby lowering the levels of TTR protein in the body. [4]
What conditions is Amvuttra approved to treat?
Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults. [4]
Are there any patient assistance programs for Amvuttra?
Yes, the Amvuttra Savings Program assists eligible commercially insured patients with their co-pay costs. [1] Details on eligibility and enrollment can be obtained through healthcare providers or the drug's manufacturer.
What is the dosage and administration of Amvuttra?
Amvuttra is administered as a subcutaneous injection. The recommended dosage is 114 mg every three months, after an initial loading dose of 114 mg at weeks 1 and 3. [4]
What are the potential side effects of Amvuttra?
Common side effects of Amvuttra include injection site reactions, pain in the extremities, and erythema. [4]
How does Amvuttra compare to other treatments for hATTR amyloidosis?
Amvuttra, as an RNAi therapeutic, offers a different mechanism of action compared to other treatments for hATTR amyloidosis, such as TTR stabilizers or tafamidis, which is a TTR protein stabilizer. Clinical studies have demonstrated its efficacy in reducing TTR protein levels and improving neuropathy. [4]
Who manufactures Amvuttra?
Amvuttra is manufactured by Alnylam Pharmaceuticals. [1]
What is the reimbursement landscape for Amvuttra?
Reimbursement for Amvuttra, like other specialty drugs, is influenced by payer policies, prior authorization requirements, and patient co-insurance. The Amvuttra Savings Program aims to mitigate out-of-pocket costs for commercially insured patients. [1]
What clinical trial data supports Amvuttra's use?
Clinical trials, such as the APOLLO-B study, have evaluated the efficacy and safety of Amvuttra in patients with hATTR amyloidosis. These studies have shown that Amvuttra can lead to significant reductions in serum TTR levels and improvements in neuropathy. [4]
Sources:
[1] https://www.amvuttra.com/savings-and-support/how-to-get-amvuttra
[2] https://www.drugs.com/price-guide/onpattro
[3] https://www.drugpatentwatch.com/
[4] https://www.amvuttra.com/